SCHEMBL16057331

SCHEMBL16057331

CCCCc1c(-c2ccc(OC)cc2)ccn(C(=O)O)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCTPP1 Q9H773 1/20 0.43
▸ CCNB2 O95067 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ CCNB1 P14635 2/20 0.40
▸ GSK3A P49840 2/20 0.40
▸ GSK3B P49841 2/20 0.40
▸ CCNB3 Q8WWL7 2/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ ZAP70 P43403 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ HPGD P15428 2/20 0.40
▸ APLNR P35414 4/20 0.39
▸ GAA P10253 3/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16056988 0.85 RARB (0.40) HPGDALDH1A1HSD17B10
SCHEMBL14977502 0.82 GCGR (0.41) DCTPP1KDM4EALDH1A1HTTLMNA
SCHEMBL16058817 0.82 PSEN1 (0.37) GAAKDM4EALDH1A1KMT2AMAPT
SCHEMBL16057776 0.78 RARB (0.46) KDM4EALDH1A1SMN1; SMN2
SCHEMBL16057557 0.77 CYP3A4 (0.47) APLNRKDM4EALDH1A1POLBKMT2A
SCHEMBL16056895 0.76 RARB (0.48) HPGDALDH1A1KMT2AHSD17B10MAPT
SCHEMBL16057538 0.76 MAPT (0.40) DCTPP1HPGDKDM4EALDH1A1POLB
SCHEMBL16057208 0.76 SLC37A4 (0.38) DCTPP1HPGDKDM4EALDH1A1LMNA
SCHEMBL7735825 0.73 GFER (0.48) GFERHPGDGAAKDM4EALDH1A1
SCHEMBL16057846 0.70 CCNB2 (0.45) DCTPP1CCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 DCTPP1 2719/4885CCNB2 3711/4885CDK1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback